Table 1 Clinical and laboratorial characteristics of Pv/HIV Co hospitalized patients at FMT-HVD
ID | Sex/age | Viral load (copies/mL) | CD4 + cell count (cells/μL) | First malaria episode/semiquantitative Parasitemia (+)c | Concomitant conditions/co-morbidities | AIDS defining illness | ARV treatment/adherence | Severe malaria (WHO criteria) |
|---|---|---|---|---|---|---|---|---|
1 | F, 22 | 19,109 | 130 | Yes/+ +  | Pregnancy (22 weeks) | No | No | No |
2 | M, 51 | 0 | 1202 | No/+ + | None | No | No | No |
3 | F, 27 | ND | 6b | No/+ | OC, TB (5th month treatment) | Yes | 3Tc + AZT + ATV/r Low adherence. | No |
4 | M, 52 | ND | ND | Yes/+ +  | None | No | 3Tc + AZT + LPV/r. Low adherence | No |
5 | F, 24 | 1,740 | 536 | No/+ +  | G6PDd | No | No | Significant bleeding (persistent brownish metrorrhagia) and respiratory distress |
6 | M, 14 | 162 | 325 | Yes/+ +  | None | No | AZT + 3Tc + LPV/r + RAL/ Low adherence. | No |
7 | M, 42 | ND | ND | No/+ +  | TB (2nd month treatment), NTX, SYP | Yes | TDF + 3Tc + EFV/ Low adherence | No |
8 | M, 27 | 58,825 | 17 | No/+ +  | TB, NTX, PNM, OC | Yes | AZT + 3Tc + LPV/r/ Low adherence. | No |
9 | M, 31 | 21,271 | 126 | Yes/+ +  | None | No | 3Tc + AZT + EFV/yes | No |
10 | M, 29 | 90,336b | 23b | No/+ + +  | AIDS wasting syndrome, GTB, SYP | Yes | No | Anemia (6.7 g/dL), pulmonary edema and respiratory distress |
11 | M, 66 | 0 | 542 | No/1/2+ | None | No | 3Tc + AZT + RTV/ Low adherence. | No |
12 | M, 26 | 14,763 | 228 | Yes/+ +  | TB (2nd month treatment) | No | 3Tc + AZT + EFV/ Started treatment at hospital. | No |
13 | M, 29 | 6894 | 266 | Yes/+ + +  | Asthma | No | 3Tc + AZT + LPV/r/ Low adherence. | No |
14 | F, 31 | 660 | 308 | No/+ +  | G6PDd | No | 3Tc + ATV + TDF/ Yes | Hyperbilirubinemia (total bilirubin = 12.09 mg/dL) + AST (81 IU/L); ALT (105 IU/L), GGT (108 IU/L), LDH (609 IU/L) |
15 | F, 19 | 88,561b | 195b | Yes/+  | NTX | Yes | No | No |
16 | F, 49 | 56b | 188b | Yes/+  | Hypertension, DM, Obesity, HCV, HerZ, AKI | Yes | 3Tc + TDF + DTG/ Yes | No |
17 | M, 13 | 230 | 417 | Yes/1/2 +  | None | No | 3Tc + AZT + LPV/r Low adherence. | No |
18 | M, 51 | NDa | NDa | No/+ +  | NTX | Yes | AZT + 3TC + LPV/r Low adherence. | No |
19 | M, 50 | 262,604 | 427 | No/+  | TB, AKI, DM, LLC, ISSO, SAL | Yes | No | Respiratory distress |
20 | M, 39 | 0b | 145b | Yes/+ + +  | None | No | AZT + 3TC + LPV/r Low adherence. | No |
21 | F, 35 | NDa | NDa | Yes/+ +  | TB, HIV associated wasting syndrome | Yes | HIV status unknown until hospitalization. No treatment. | Hyperbilirubinemia (5.71 mg/dL) + AST (558 IU/L) and GGT (441 IU/L) associated to other organ dysfunction, AKI (creatinine 4.5 mg/dL), metabolic acidosis and respiratory distress |